Delayed
Japan Exchange
12:04:09 2024-05-08 am EDT
|
5-day change
|
1st Jan Change
|
559
JPY
|
-2.61%
|
|
+4.29%
|
+14.31%
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,070
|
1,893
|
1,749
|
2,284
|
1,734
|
1,649
|
Enterprise Value (EV)
1 |
-224.9
|
-478
|
197.1
|
675.1
|
274.3
|
29.42
|
P/E ratio
|
414
x
|
14.7
x
|
-25
x
|
-18.4
x
|
-14.1
x
|
-30
x
|
Yield
|
3.92%
|
4.29%
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.38
x
|
0.33
x
|
0.75
x
|
10.2
x
|
3.45
x
|
0.56
x
|
EV / Revenue
|
-0.04
x
|
-0.08
x
|
0.08
x
|
3.01
x
|
0.55
x
|
0.01
x
|
EV / EBITDA
|
-37.5
x
|
-3.1
x
|
-0.75
x
|
-1.35
x
|
-0.69
x
|
-0.25
x
|
EV / FCF
|
4.71
x
|
-3.05
x
|
-0.22
x
|
-2.89
x
|
-0.98
x
|
0.21
x
|
FCF Yield
|
21.2%
|
-32.8%
|
-463%
|
-34.6%
|
-102%
|
474%
|
Price to Book
|
1.01
x
|
0.91
x
|
0.89
x
|
1.23
x
|
1
x
|
0.99
x
|
Nbr of stocks (in thousands)
|
3,690
|
3,690
|
3,690
|
3,690
|
3,690
|
3,690
|
Reference price
2 |
561.0
|
513.0
|
474.0
|
619.0
|
470.0
|
447.0
|
Announcement Date
|
12/25/18
|
12/23/19
|
12/25/20
|
12/27/21
|
12/26/22
|
12/26/23
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5,416
|
5,727
|
2,347
|
224
|
502
|
2,945
|
EBITDA
1 |
6
|
154
|
-262
|
-499
|
-396
|
-117
|
EBIT
1 |
2
|
150
|
-267
|
-505
|
-401
|
-121
|
Operating Margin
|
0.04%
|
2.62%
|
-11.38%
|
-225.45%
|
-79.88%
|
-4.11%
|
Earnings before Tax (EBT)
1 |
7
|
166
|
-62
|
-109
|
-105
|
-54
|
Net income
1 |
5
|
129
|
-70
|
-124
|
-123
|
-55
|
Net margin
|
0.09%
|
2.25%
|
-2.98%
|
-55.36%
|
-24.5%
|
-1.87%
|
EPS
2 |
1.355
|
34.96
|
-18.97
|
-33.60
|
-33.33
|
-14.91
|
Free Cash Flow
1 |
-47.75
|
156.8
|
-912.9
|
-233.6
|
-280.6
|
139.4
|
FCF margin
|
-0.88%
|
2.74%
|
-38.9%
|
-104.3%
|
-55.9%
|
4.73%
|
FCF Conversion (EBITDA)
|
-
|
101.79%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
121.51%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
22.00
|
22.00
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/25/18
|
12/23/19
|
12/25/20
|
12/27/21
|
12/26/22
|
12/26/23
|
Fiscal Period: September |
2020 S1
|
2021 S1
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2024 Q1
|
2024 S1
|
---|
Net sales
1 |
2,326
|
126
|
123
|
183
|
137
|
409
|
958
|
942
|
883
|
2,072
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
19
|
-258
|
-102
|
-212
|
-92
|
-90
|
-140
|
2
|
-24
|
5
|
Operating Margin
|
0.82%
|
-204.76%
|
-82.93%
|
-115.85%
|
-67.15%
|
-22%
|
-14.61%
|
0.21%
|
-2.72%
|
0.24%
|
Earnings before Tax (EBT)
1 |
31
|
-64
|
-20
|
-36
|
-23
|
-62
|
-94
|
10
|
-18
|
14
|
Net income
1 |
21
|
-70
|
-25
|
-45
|
-28
|
-62
|
-95
|
11
|
-18
|
10
|
Net margin
|
0.9%
|
-55.56%
|
-20.33%
|
-24.59%
|
-20.44%
|
-15.16%
|
-9.92%
|
1.17%
|
-2.04%
|
0.48%
|
EPS
2 |
5.960
|
-19.09
|
-6.930
|
-12.40
|
-7.650
|
-16.94
|
-25.95
|
2.960
|
-5.150
|
2.890
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
5.000
|
Announcement Date
|
5/7/20
|
5/6/21
|
1/31/22
|
5/6/22
|
8/1/22
|
1/31/23
|
5/8/23
|
7/31/23
|
1/31/24
|
5/7/24
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,295
|
2,371
|
1,552
|
1,609
|
1,460
|
1,620
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-47.8
|
157
|
-913
|
-234
|
-281
|
139
|
ROE (net income / shareholders' equity)
|
0.24%
|
6.24%
|
-3.45%
|
-6.49%
|
-6.88%
|
-3.24%
|
ROA (Net income/ Total Assets)
|
0.04%
|
2.79%
|
-5.93%
|
-14.6%
|
-11.6%
|
-3.13%
|
Assets
1 |
13,514
|
4,628
|
1,180
|
847.2
|
1,058
|
1,760
|
Book Value Per Share
2 |
556.0
|
565.0
|
535.0
|
501.0
|
468.0
|
453.0
|
Cash Flow per Share
2 |
622.0
|
643.0
|
421.0
|
436.0
|
396.0
|
439.0
|
Capex
1 |
2
|
2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.04%
|
0.03%
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/25/18
|
12/23/19
|
12/25/20
|
12/27/21
|
12/26/22
|
12/26/23
|
|
1st Jan change
|
Capi.
|
---|
| +14.31% | 12.94M | | +1.64% | 122B | | +46.35% | 34.84B | | -25.61% | 15.37B | | +52.85% | 8.04B | | +44.04% | 6.35B | | +18.35% | 3.55B | | +3.34% | 2.92B | | +13.69% | 2.11B | | +3.70% | 2.02B |
Travel Agents
|